AUS
NZ
UK
CA
USA
IND
Highlights:
- Funding Achievement: Lumos Diagnostics Holdings Ltd (ASX: LDX, OTC: LDXHF) has secured approximately US$2,984,571 from BARDA to advance its FebriDx® diagnostic tool.
- Rapid Diagnostic Capabilities: FebriDx® utilizes a fingerstick blood sample to deliver results in 10 minutes, helping differentiate between bacterial and viral infections to improve antibiotic stewardship.
- Regulatory and Market Potential: The funding will support CLIA waiver studies and FDA regulatory submissions, with a potential contract value exceeding US$8.25 million, expanding the use of FebriDx® in point-of-care settings.
Lumos Diagnostics Holdings Ltd (ASX:LDX) has announced a significant funding milestone for its FebriDx® bacterial testing technology, securing nearly US$2,984,571 in non-dilutive funding from the US Biomedical Advanced Research and Development Authority (BARDA). This funding is intended to advance the development and deployment of the FebriDx® diagnostic tool, which is pivotal in differentiating between bacterial and non-bacterial infections.
Overview of FebriDx® Technology
FebriDx® is a cutting-edge diagnostic tool that utilizes a fingerstick blood sample to swiftly distinguish between bacterial and viral infections, providing results in as little as 10 minutes. The primary objective of this technology is to enhance antibiotic use decisions, which aligns with global efforts to combat antibiotic resistance through improved antibiotic stewardship practices. This rapid testing capability is especially vital in clinical settings where timely diagnosis can significantly influence treatment pathways.
Funding Implications and Regulatory Pathway
The recent funding will facilitate Lumos Diagnostics in conducting a clinical laboratory improvement amendments (CLIA) waiver study, which is essential for gaining regulatory approval from the US Food and Drug Administration (FDA). If successful, FebriDx® could be utilized in CLIA-waived point-of-care settings, including physician offices and urgent care clinics.
The contract value holds the potential to exceed US$8.25 million if all options outlined in the agreement are exercised. This additional funding underscores the confidence placed in Lumos’ technology by BARDA and highlights the growing need for rapid diagnostic tools in outpatient care environments.
Addressing Antibiotic Over-Prescription
The FebriDx® technology is positioned as a critical solution in the fight against the over-prescription of antibiotics, an issue that has reached concerning levels in clinical settings. By enabling healthcare providers to quickly ascertain the nature of an infection, FebriDx® aims to reduce unnecessary antibiotic usage, thereby contributing to better patient outcomes and supporting public health initiatives aimed at preserving antibiotic efficacy.
